Michelle Cilento
Physician Assistant · Rochester, NYNPI 1548299316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,559 and has fallen 70.7% since, to $456 in 2025. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$904
- Sumitomo Pharma America, Inc.$792
- Johnson & Johnson$788
- Pfizer$457
- Urovant Sciences Inc$215
- Teleflex LLC$197
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,30795%
- Education$2735%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 57 | $904 |
| Sumitomo Pharma America, Inc. | 36 | $792 |
| Johnson & Johnson(2 entities) | 29 | $788 |
| Pfizer | 28 | $457 |
| Urovant Sciences Inc | 10 | $215 |
| Teleflex LLC | 3 | $197 |
| Antares Pharma, Inc. | 6 | $195 |
| Medtronic | 6 | $183 |
| Ferring Pharmaceuticals Inc. | 3 | $155 |
| AbbVie(2 entities) | 7 | $147 |
| Myriad Genetic Laboratories, Inc. | 1 | $144 |
| Tolmar, Inc. | 6 | $136 |
| Endo Pharmaceuticals Inc. | 7 | $124 |
| Procept Biorobotics Corporation | 1 | $123 |
| Incyte Corporation | 1 | $100 |
| Myovant Sciences Inc. | 7 | $100 |
| Blue Earth Diagnostics | 4 | $95 |
| Tolmar Pharmaceuticals, Inc. | 5 | $91 |
| Urogen Pharma, Inc. | 4 | $86 |
| Merck | 4 | $86 |
| Axonics, Inc. | 2 | $70 |
| Coloplast | 3 | $55 |
| Dendreon Pharmaceuticals LLC | 3 | $51 |
| Dentsply IH AB | 2 | $44 |
| Bayer | 2 | $44 |
| Novo Nordisk | 2 | $36 |
| Clarus Therapeutics Inc. | 2 | $35 |
| Novartis | 1 | $25 |
| Endo USA, Inc. | 1 | $21 |
| 180 Medical, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Immunitybio, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$147
- AquaBeam Robotic System$123
- GEMTESA$118
- ADSTILADRIN$111
- Erleada$111
How this compares
$5,580 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 15 | $208,535 |
| GemtesaVibegron | 195 | $166,817 |
| MyrbetriqMirabegron | 211 | $149,246 |
| Mirabegron ErMirabegron | 57 | $26,402 |
| Testosterone | 40 | $12,828 |
| Tamsulosin Hcl | 764 | $12,118 |
| BotoxOnabotulinumtoxina | 15 | $11,603 |
| Trospium Chloride | 147 | $10,097 |
| XyostedTestosterone Enanthate | 12 | $9,644 |
| Finasteride | 383 | $5,365 |
| Testosterone Cypionate | 91 | $5,125 |
| Methenamine Hippurate | 50 | $4,954 |
| Silodosin | 30 | $2,971 |
| Solifenacin Succinate | 89 | $2,847 |
| Oxybutynin Chloride ErOxybutynin Chloride | 129 | $2,749 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $904 | $357,782226 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $792 | $166,817195 claims |
| AbbVieBotox | $147 | $11,60315 claims |
| Antares Pharma, Inc.Xyosted | $195 | $9,64412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Rochester
- Jennifer ServentiRochester$160K
- Sarah EnslinRochester$74K
- Bridget SkinnerRochester$25K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
- Kaitlyn NelsonBrooklyn$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.